Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2024-01-25 00:00:00 ET · period of report 2024-01-23 · accession 0001968202-24-000041 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-01-25 | 2024-01-23 | REGN | Fenimore Christopher R. | SVP Ctrl | M - OptEx | $477.67 | +10.0K | 22.9K | +78% | +$4.78M |
| DM | 2024-01-25 | 2024-01-23 | REGN | Fenimore Christopher R. | SVP Ctrl | F - Tax | $948.50 | -7,569 | 17.9K | -30% | -$7.18M |
| DM | 2024-01-25 | 2024-01-23 | REGN | Fenimore Christopher R. | SVP Ctrl | M - OptEx | $0.00 | -10.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-23 | M | A | 5,000 | $555.67 | 21,860 | D | — | — | |
| 2 | Common | Common Stock | 2024-01-23 | F | D | 3,583 | $948.50 | 19,291 | D | — | — | |
| 3 | Common | Common Stock | 2024-01-23 | M | A | 5,000 | $399.66 | 22,874 | D | — | — | |
| 4 | Common | Common Stock | 2024-01-23 | F | D | 3,986 | $948.50 | 17,874 | D | — | — | |
| 5 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-01-23 | M | D | 5,000 | $0.00 | 0 | D | $555.67 · — to 2025-12-16 | 5,000 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |
| 6 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-01-23 | M | D | 5,000 | $0.00 | 0 | D | $399.66 · — to 2024-12-16 | 5,000 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |